Table. 2.

Percentage of the instruments used for the therapeutic drug monitoring proficiency testing during 2015–2019

Name of instrument Year

2015 2016 2017 2018 2019
Abbott Architect i System 46.4 49.2 46.9 47.4 45.1
Roche Cobas c311/c501/c502/c702 6.0 - 5.0 11.8 17.2
LC-MS/MS 1.8 4.3 6.7 8.2 10.1
Roche Cobas Integra 18.0 18.6 16.9 11.1 5.7
Siemens Dimension 3.7 2.9 3.7 4.2 5.4
Roche Cobas E170/e411/e601/e602/e801 - 4.5 4.3 4.4 4.0
Siemens ADVIA Centaur 3.2 3.9 4.2 4.0 3.4
Beckman Olympus AU Series 1.0 1.6 1.4 1.4 1.6
Ortho Vitros5600 - 0.2 - - 1.1
Roche AVL9180 - 0.3 0.7 0.8 1.0
Nova 4 Analyzer - - 0.6 0.7 0.9
Roche/Hitachi Systems 3.8 1.2 0.9 0.7 0.7
Toshiba Chemistry Analyzer 1.2 0.7 0.3 0.3 0.7
Roche 9100 Series (ISE mode) 0.2 0.8 0.7 0.7 0.5
ICP-MS 0.1 0.2 0.2 0.2 0.2
Hitachi AP720 - - 0.9 0.2 0.2
Atomic Absorption Spectrometers 0.3 0.4 0.2 0.2 0.2
Radioimmunoassay 0.3 0.2 0.2 0.2 0.2
Siemens Viva-E 2.2 1.1 1.0 0.2 0.2
Beckman UniCel DxI800 - 1.1 0.2 0.2 0.1
Siemens Vista 0.7 0.5 0.3 0.2 0.1
Siemens Atellica CH 930 Analyzer - - - - 0.1
GC-MS - - - 0.1 -
Beckman UniCel DxC Synchron 3.3 1.7 0.2 - -
Others 7.8 6.7 4.7 3.2 1.6
Total 100.0 100.0 100.0 100.0 100.0

Values are presented as %. The instruments were from the following companies: Abbott Laboratories (Chicago, IL, USA), Roche Diagnostics (Mannheim, Germany), Siemens (Erlangen, Germany), Beckman Coulter Inc. (Brea, CA, USA), Ortho Clinical Diagnostics (Raritan, NJ, USA), Nova Biomedical Corp. (Waltham, MA, USA), Toshiba Medical Systems (Tokyo, Japan), and Hitachi High-Technologies Corp. (Tokyo, Japan). Instruments of the same series are combined, and some minor instruments with various manufacturers are substituted as their methods: liquid chromatography-tandem mass spectrometry (LC-MS/MS), inductively coupled plasma-mass spectrometry (ICP-MS), radioimmunoassay, gas chromatography–mass spectrometry (GC-MS), and atomic absorption spectrometry.

J Lab Med Qual Assur 2020;42:183~193 https://doi.org/10.15263/jlmqa.2020.42.4.183
© Lab Med Qual Assur